Teclistamab Induced a Profound Hematologic Response in Light Chain Deposition Disease With Probable Cardiac Involvement.
Xinyi Xiong, Danqing Zhao, Jian Li et al.
✦ AI-curated · Sources linked
Case in brief
A 63-year-old man had κ-light chain deposition disease involving the kidneys, with probable cardiac involvement. After an initial response to daratumumab-pomalidomide-dexamethasone, he developed hematologic relapse. Salvage treatment with the BCMA × CD3 bispecific antibody teclistamab produced a rapid, sustained hematologic complete response. No cytokine release syndrome or neurotoxicity was reported, and renal and cardiac function remained stable.
What made this case unusual
The report describes teclistamab use for light chain deposition disease, a rare plasma cell disorder, after relapse following daratumumab-based therapy.
Diagnostic / clinical pearl
In this case, teclistamab achieved a sustained hematologic complete response after relapse, without reported cytokine release syndrome or neurotoxicity; renal and cardiac function remained stable.
Why it matters
The case offers early evidence that BCMA-directed immunotherapy may be a salvage option for this rare disorder, although a single report cannot establish broader efficacy.